Latest News for Techno Horizon Stock (OTC:THHCF)

Techno Horizon Co Ltd is a Japan-based company engaged in optical business and electronic business. The company manufactures and sells optical, electrical, medical, and precision equipment; develops, manufactures, and sells information and communication equipment, FA related equipment, and other electronic devices; and produces and sells various optical lenses and plastic moulded products, as well as provides system integration services.

TECHNO HORIZON CO LTD by Techno Horizon Co Ltd.

Techno Horizon Co Ltd

HC Wainwright &amp; Co. analyst Andrew Fein maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $325 to $300.

News

Price Target

Analyst Ratings

BIIB

HC Wainwright & Co. Maintains Buy on Biogen, Lowers Price Target to $300

Rosenblatt analyst Barton Crockett maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $520 to $562.

Rosenblatt Maintains Buy on Meta Platforms, Raises Price Target to $562

Market-Moving Exclusives

Exclusives

VRAX

EXCLUSIVE: Virax Biolabs Tells Benzinga 'The launch marks a significant milestone for Virax as it brings us a step closer to commercializing ViraxImmuneTM  as a full In-Vitro-Diagnostic product'

Darling Ingredients (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.46 by 8.7 percent. This is a 56.14 percent decrease over earnings of $1.14 per share from the same period last year. The company reported quarterly sales of $1.420 billion which missed the analyst consensus estimate of $1.484 billion by 4.26 percent. This is a 20.71 percent decrease over sales of $1.791 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Darling Ingredients Q1 2024 GAAP EPS $0.50 Beats $0.46 Estimate, Sales $1.420B Miss $1.484B Estimate

WIIM

Brunswick shares are trading lower following Q1 financial results and roughly in-line guidance.

EXCLUSIVE: Virax Biolabs Tells Benzinga Co. Launches Portfolio Of Immune Profiling Solutions Evaluating Adaptive Immunity In Post-Viral Syndromes

ConnectOne Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNOB#NASDAQ">CNOB</a>) reported quarterly earnings of $0.41 per share which missed the analyst consensus estimate of $0.42 by 2.38 percent. This is a 30.51 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $60.300 million which missed the analyst consensus estimate of $61.598 million by 2.11 percent. This is a 10.11 percent decrease over sales of $67.084 million the same period last year.

CNOB

ConnectOne Bancorp Q1 2024 GAAP EPS $0.41 Misses $0.42 Estimate, Sales $60.300M Miss $61.598M Estimate

BlackRock&#8216;s iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) has seen its <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38401088/bitcoin-spot-etfs-net-31-6m-inflows-as-hong-kong-readies-for-etf-launches">record-breaking streak of inflows</a> come to an end on Wednesday. 
What Happened: According to <a href="https://sosovalue.xyz/assets/etf">data </a>from SoSoValue, IBIT recorded no net inflows for the day, snapping a 71-day stretch of continuous investment. 
On Wednesday, spot Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ETF flows saw net outflows totaling $121 million, signaling a turbulent day for cryptocurrency investments.
Notably, Grayscale's Bitcoin Trust ETF (GBTC) registered the most substantial single-day outflow, withdrawing $130 million. 
Contrasting this, Fidelity Wise&#8217;s Origin Bitcoin Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>) emerged as the frontrunner for inflows, attracting $5.61 million in a single day, followed closely by the collaborative ETF from Ark Invest and 21Shares (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>), which saw an influx of $4.17 million.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38413962/jack-dorsey-wants-to-make-bitcoin-mining-as-easy-as-plugging-in-a-lamp-heres-how">Jack Dorsey Wants To Make Bitcoin Mining As Easy As Plugging In A Lamp: Here&#8217;s How</a>
Hong Kong Steps Into The Crypto ETF Arena
The news of BlackRock&#8217;s pause coincides with a significant development in the Asian market. 
HashKey Exchange announced the completion of the first-ever cryptocurrency subscription for Bitcoin and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) spot ETFs offered by Hong Kong-based Bosera International and HashKey Capital. 
This subscription model allows for redemption without immediate sale of the underlying assets, potentially offering cost and liquidity benefits to investors.
Hong Kong&#8217;s foray into cryptocurrency ETFs marks a potential turning point for the Asian market. 
These ETFs are expected to begin trading on the Hong Kong Stock Exchange on April 30, providing investors in the region with a new avenue for cryptocurrency exposure.
What&#8217;s Next: The Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event, scheduled for Nov. 19, will convene industry leaders, analysts, and investors to discuss these critical developments. 
This conference presents a unique opportunity to gain insights into the future of Bitcoin ETFs, cryptocurrency subscriptions, and the broader digital asset ecosystem. 
Don&#8217;t miss out on this chance to stay ahead of the curve in this <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38412858/trumps-crypto-portfolio-rebounds-with-1m-weekly-profit-which-crazy-new-currencies-does-he-">rapidly changing market.</a>
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38408395/why-is-mog-crypto-coin-going-up-trader-sees-billions-as-price-target">Why Is MOG Crypto Coin Going Up? Trader Sees &#8216;Billions&#8217; As Price Target</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

IBIT

BlackRock's Spot Bitcoin ETF Sees Zero Inflows, As Net Outflows Tally $130M On Wednesday

Jason Tsai, currently VP of IR and Finance at Silicon Motion, has been appointed Interim Chief Financial Officer of the Company effective as of April 25, 2024.&nbsp;

Management

SIMO

Silicon Motion Says Riyadh Lai Will Be Stepping Down As CFO, Effective April 25, 2024; Jason Tsai Named As Interim CFO

Craig-Hallum analyst Jeremy Hamblin initiates coverage on Red Robin Gourmet Burgers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>) with a Buy rating and announces Price Target of $20.

Initiation

RRGB

Craig-Hallum Initiates Coverage On Red Robin Gourmet Burgers with Buy Rating, Announces Price Target of $20

CARR

Carrier Global shares are trading higher, rebounding from earlier weakness following Q1 earnings.

Latest version enhances operational efficiency, regulatory reporting, and strategic decision-making with robust business insights

Tech

General

SPNS

Sapiens Unveils Enhanced Reinsurance and Analytics Solution Catering to Evolving Market Demands

California Water Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWT#NYSE">CWT</a>) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $0.36 by 236.11 percent. This is a 402.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $270.75 million which beat the analyst consensus estimate of $183.85 million by 47.27 percent. This is a 106.52 percent increase over sales of $131.10 million the same period last year.

California Water Servs Gr Q1 EPS $1.21 Beats $0.36 Estimate, Sales $270.75M Beat $183.85M Estimate

Commodities

Markets

LODE

Comstock Completed The Commissioning Stages Of Its Demonstration-scale Production Facility In Silver Springs, Nevada

Buybacks

Union Pacific Says Restarting Share Repurchases In Q2

Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) reported quarterly earnings of $2.69 per share which beat the analyst consensus estimate of $2.52 by 6.75 percent. The company reported quarterly sales of $6.00 billion which beat the analyst consensus estimate of $5.98 billion by 0.26 percent. This is a 0.92 percent decrease over sales of $6.06 billion the same period last year.

Union Pacific Q1 2024 Adj EPS $2.69 Beats $2.52 Estimate, Sales $6.00B Beat $5.98B Estimate

ULBI

Ultralife shares are trading higher after the company reported better-than-expected Q1 financial results.

2024 Full Year&nbsp;Guidance:
The Company reaffirms its FY 2024&nbsp;outlook&nbsp;for net sales of&nbsp;$3.42 billion&nbsp;to&nbsp;$3.58 billion, adjusted sales of&nbsp;$3.40 billion&nbsp;to&nbsp;$3.55 billion, net earnings and margin of&nbsp;$125 million&nbsp;to&nbsp;$160 million&nbsp;and&nbsp;3.7%&nbsp;to&nbsp;4.5%, respectively, adjusted EBITDA of&nbsp;$470 million&nbsp;to&nbsp;$510 million, and adjusted EBITDA margin of&nbsp;13.8%&nbsp;to&nbsp;14.4%. PHINIA expects to generate&nbsp;$160 million&nbsp;to&nbsp;$200 million&nbsp;in adjusted free cash flow. Adjusted tax rate is expected to be in the range of&nbsp;28%&nbsp;to&nbsp;32%.

Guidance

PHIN

PHINIA Reaffirms 2024 Outlook For Net Sales Of $3.42B-$3.58B, Adjusted Sales Of $3.40B-$3.55B Vs. $3.48B Consensus; Expects To Generate $160M-$200M In Adjusted Free Cash Flow

Summit Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMF#NASDAQ">SMMF</a>) reported quarterly earnings of $1.14 per share which beat the analyst consensus estimate of $1.07 by 6.54 percent. This is a 3.64 percent increase over earnings of $1.10 per share from the same period last year. The company reported quarterly sales of $45.001 million which beat the analyst consensus estimate of $44.674 million by 0.73 percent. This is a 16.66 percent increase over sales of $38.575 million the same period last year.

SMMF

Summit Finl Gr Q1 2024 GAAP EPS $1.14 Beats $1.07 Estimate, Sales $45.001M Beat $44.674M Estimate

Thursday,&nbsp;Virax Biolabs Group Limited&nbsp;(NASDAQ:&nbsp;VRAX) announced it is launching ‘ImmuneSelect' within the ViraxImmune T-Cell diagnostic platform for research-use-only (RUO) at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 Congress.
"We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs.
"The launch marks a significant milestone for Virax, as it brings us a step closer to commercializing ViraxImmune as a full in-Vitro Diagnostic product."&nbsp;
ImmuneSelect is the company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity.&nbsp;
ImmuneSelect&nbsp;is developed&nbsp;to evaluate T-Cell driven immunity and to aid in the understanding and early characterization of symptoms associated with post-viral syndromes, including&nbsp;Long&nbsp;COVID.
Products within the ImmuneSelect brand are for research and investigational use only and&nbsp;are not intended&nbsp;to&nbsp;be used&nbsp;as a diagnostics tool.&nbsp;
The ImmuneSelect portfolio includes peptide pools covering epitopes from pathogens linked to post-viral syndromes.&nbsp;
These include pools for SARS-CoV-2, SARS-CoV-2 MHC-1 (CD8), Lyme Disease, Cytomegalovirus, Respiratory Syncytial Virus, and Epstein-Barr Virus.&nbsp;
ImmuneSelect's Recombinant Antibodies target cytokines and biomarkers, and they are available in different versions unconjugated to&nbsp;be tested&nbsp;on a range of applications, including Flow Cytometry, ELISA, and ELISpot/Fluorospot.&nbsp;
Dr. Nigel McCracken, the Chief Operations Officer of Virax Biolabs, said, "We believe there is great potential to utilize T-Cell diagnostics to help detect underlying post-viral infections by initially measuring the body's adaptive immune resistance to infections and then monitoring the potential progression of an individual's T-Cell functions following chronic antigen stimulation."
Price Action:&nbsp;VRAX shares closed at $0.66 on Wednesday.